The Journal of Urology
Volume 178, Issue 3 , Pages 769-774 , September 2007

Overactive Bladder in Children. Part 2: Management

  • Israel Franco

      Affiliations

    • Corresponding Author InformationCorrespondence: Pediatric Urology Associates, P. C., 19 Bradhurst Ave., suite 2575, Hawthorne, New York 10532 (telephone: 1-914-493-8628; FAX: 1-914-493-8564).

Received 16 January 2007

References 

  1. Van Arendonk KJ, Austin JC, Boyt MA, Cooper CS. Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder. Urology. 2006;67:1049
  2. Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha adrenergic antagonists. J Urol. 2005;173:212
  3. Oger S, Behr-Roussel D, Bernabe J, Denys P, Camperat E, Lebret T, et al. Influence of the inhibition of cyclic nucleotide phosphodiesterase type 4 on human detrusor smooth muscle contractions. J Urol. 2006;175(suppl.):63;abstract 194
  4. Werkstrom V, Andersson K, Svensson A, Hedlund P. Phosphodiesterase 5 in the pig and human urethra: morphological and functional aspects. J Urol. 2006;175(suppl.):55;abstract 170
  5. Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics. 1997;100:228
  6. Homsy YL, Austin PF. Dysfunctional voiding disorders and nocturnal enuresis. In:  Belman AB,  King LR,  Kramer SA editor. Clinical Pediatric Urology. London: Martin Dunitz Ltd; 2002;p. 345–370
  7. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818
  8. Schonwald A, Sherritt L, Stadtler A, Bridgemohan C. Factors associated with difficult toilet training. Pediatrics. 2004;113:1753
  9. Kamm MA. Pharmacological treatment of irritable bowel syndrome—from concept to sales. Eur J Surg. 2002;(suppl.):10
  10. Waring WS, Chui M, Japp A, Nico EF, Ford MJ. Autonomic cardiovascular responses are impaired in woman with irritable bowel syndrome. J Clin Gastroenterol. 2004;38:658
  11. Chang I. Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder?. Gastroenterol Clin North Am. 2005;34:271
  12. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171:2128
  13. Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen , et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive bladder. J Urol. 2006;176:328
  14. Steinhardt GF, Naseer S, Cruz OA. Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding. J Urol. 1997;158:190
  15. Diaz-Soldano D, Maizels M, Houston JT, Palmer JS, Richards I and Firlit C: Problems with urinary control. Presented at annual meeting of Section of Urology, American Academy of Pediatrics, San Francisco, California, October 20–24, 2001.
  16. Radojicic ZI, Perovic SV, Milic NM. Is it reasonable to treat refractory voiding dysfunction in children with botulinum A toxin?. J Urol. 2006;176:332
  17. Dyer L, Isom-Batz G, Zelkovic P, Franco I. Endoscopic botulinum A toxin injection of the external sphincter for refractory non-neurogenic voiding dysfunction: an initial series. J Urol. 2006;175(suppl.):254

    abstract 785

  18. Palmer LS, Franco I, Rotario P, Reda EF, Friedman SC, Kolligan ME, et al. Biofeedback therapy expedites the resolution of reflux in older children. J Urol. 2002;168:1699
  19. Combs AJ, Grafstein N, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in children and adolescents I: pelvic floor electromyography lag time—a new noninvasive method to screen for and monitor therapeutic response. J Urol. 2005;173:207
  20. Kiddoo DA, Canning DA, Snyder HM, Carr MC. Urethral dilation as treatment for neurogenic bladder. J Urol. 2006;176:1831
  21. Wang SC, Mcguire EJ, Bloom DA. Urethral dilation in the management of urological complications of myelodysplasia. J Urol. 1989;142:1054
  22. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268
  23. Humphreys MR, Vandersteen DR, Slezak JM, Hollatz P, Smith CA, Smith JA, et al. Preliminary results of sacral neuromodulation in 23 children. J Urol. 2006;176:2227
  24. van Balken MR, Vergunst H, Bemelmans BL. The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol. 2004;172:846
  25. Hoebeke P, Renson C, Petillon L, Vande Walle J, De Paepe H. Percutaneous electrical nerve stimulation in children with therapy resistant nonneuropathic bladder sphincter dysfunction: a pilot study. J Urol. 2002;168:2605
  26. Herz D, Weiser A, Collett T, Reda E, Levitt S, Franco I. Dysfunctional elimination syndrome as an etiology of idiopathic urethritis in childhood. J Urol. 2005;173:2132
  27. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174:1327
  28. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol. 1999;162:82
  29. Oelke M, Roovers JP, Michel MC. Safety and tolerability of duloxetine in women with stress urinary incontinence. BJOG. 2006;113:22

PII: S0022-5347(07)01284-0

doi: 10.1016/j.juro.2007.05.076

The Journal of Urology
Volume 178, Issue 3 , Pages 769-774 , September 2007

Article Tools